Twist Antibody Optimization Platform


Quickly generate high-diversity, high-quality molecules inspired by human and non-human repertoires


Why TAO?

Using a wide sequence space of tens of millions of natural human antibody sequences, Twist creates an optimization library that precisely matches the human repertoire.


- Liabilities are removed, e.g. isomerization, cleavage, deamidation, glycosylation sites, liability dipeptide motifs
- Rational sampling from desired sequence space
- · Workflows available for non-human species (e.g. felis or canis)
- Accurate representation: motif sequences explicitly encoded in oligos
- With our silicon-based DNA writing platform, have confidence that accurate, clone-perfect sequences are made when producing antibodies for screening

How it works: canonical humanization workflow shown





Using Twist Antibody Optimization, PD-1 Inhibitors Have Higher Affinity and Potency




Multiple Optimized Leads Block the PD-1/PD-L1 Interaction

CLONE	SPR KD (nM)	IC50 (nM)	BMAX (RU)	
PD1_TA01	4.5	0.434	693	٦
PD1_TA015	7.3	0.562	634	
PD1_TA091	9.2	0.868	664	
PD1_TA02	9.8	0.848	661	
PD1_TA07	10.5	0.896	642	
PD1_TA075	11.2	0.418	614	
Nivolumab	14.5	1.345	628	
PD1_TA060	16.5	1.614	776	
PD1_TA08	78.1	1.968	436	
PD1_TA058	96.7	3,384	446	
PD1_TA080	125	2.129	450	
Parental	325	4.122	449	

Addition of anti-PD1 antibody blocks the PD-1/PD-L1 interaction, releases inhibitory signal and results in TCR activation and NFAT-RE-mediated luminescence (RU).

• After Twist Antibody Optimization:

- Binding affinity went up 72×
- Function increased by 9.5×
- Six antibodies identified with higher binding affinity and function than nivolumab



PD-1/PD-L1 BLOCKADE ASSAY VS. MONOVALENT BINDING AFFINITY

PARTNER WITH US. Get in touch at biopharma@twistbioscience.com or learn more at twistbiopharma.com